China Releases Q1 Economic Report On Pharmaceutical Industry
This article was originally published in PharmAsia News
China's National Development and Reform Commission (NDRC) has released the Q1 2008 report on the economic progress of key industries. The economic profit of the pharmaceutical industry increased 18.6 percent compared to the same period last year. Chemical medicine output hit 783,000 tonnes while patented Chinese medicine reached 273,000 tonnes, with increases of 11.7 and 10.2 percent, respectively. In the first two months of this year, the pharmaceutical industry realized a profit of 9.41 billion yuan, 50.1 percent higher than the same period in 2007. NDRC forecasts that the growth in output and sales will continue to maintain a level of over 20 percent for this year. With the government's growing investment in health care and tighter industrial supervisory policies, observers are positive about the pharmaceutical industry's outlook. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.